Diarect

Baden-baden, Germany Founded: 1998 • Age: 28 yrs Acquired By BBI Group
Recombinant and native antigens
Request Access

About Diarect

Diarect is a company based in Baden-baden (Germany) founded in 1998 by Bodo Liedvogel and Heinz Haubruck was acquired by BBI Group in June 2020.. The company has 289 employees as of January 31, 2022. Diarect operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Baden-baden, Germany
  • Employees 289 as on 31 Jan, 2022
  • Founders Bodo Liedvogel, Heinz Haubruck
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Bbi Solutions Oem Limited
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $700.09 K (USD), Grant

    Jul 01, 2016

  • Investors
  • Employee Count
    289

    as on Jan 31, 2022

  • Acquired by
    BBI Group

    (Jun 04, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Diarect

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $700,085
  • First Round

    (01 Jul 2016)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2016 Amount Grant - Diarect Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Diarect

Diarect has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and BBI Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Instruments and reagents are supplied for diagnostic and healthcare sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Diarect

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Diarect

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Diarect Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Diarect

Diarect operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
CRISPR-engineered cell and gene therapies are developed for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Diarect

Bbi Group Completes Major German Acquisition
Insidermedia5 years ago

Frequently Asked Questions about Diarect

When was Diarect founded?

Diarect was founded in 1998 and raised its 1st funding round 18 years after it was founded.

Where is Diarect located?

Diarect is headquartered in Baden-baden, Germany. It is registered at Baden-baden, Baden-wurttemberg, Germany.

How many employees does Diarect have?

As of Jan 31, 2022, the latest employee count at Diarect is 289.

What does Diarect do?

Diarect specializes in the development and production of recombinant and native antigens that are used in the development of immunoassays. The company manufactures a host of allergens (found in food, grasses and trees), a large collection of autoimmune disease antigens (including, SARD, Mixed Connective Tissue Disease, SLE, Sjøgrens Syndrome, Systemic Sclerosis CREST Syndrome, Polymyositis Dermatomyositis, Autoimmune Thyroid Diseases, Celiac Disease, Autoimmune Hepatitis, Primary Biliary Cirrhosis, ANCA-Associated Diseases, Antiphospholipid Syndrome Thromboembolic Syndrome, Anti-GBM Disease, Diabetes Mellitus, Pernicious Anemia, Crohns Disease), and infectious disease antigens (including Anaplasmosis, Babesiosis, Borreliosis Lyme Disease Relapsing Fever, Candidiasis, Erythema infectiosum, Scarlet Fever, Yersiniosis). The company is also the European distributor of SurModics protein stabilization reagents and blockers and BioFX substrates.

Who are the top competitors of Diarect?

Diarect's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are Diarect's investors?

Diarect has 2 investors. Key investors include European Union, and BBI Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available